KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Emergent BioSolutions (EBS) FCF Margin (2016 - 2025)

Historic FCF Margin for Emergent BioSolutions (EBS) over the last 17 years, with Q3 2025 value amounting to 2.47%.

  • Emergent BioSolutions' FCF Margin fell 528100.0% to 2.47% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.18%, marking a year-over-year decrease of 148200.0%. This contributed to the annual value of 3.43% for FY2024, which is 280100.0% up from last year.
  • According to the latest figures from Q3 2025, Emergent BioSolutions' FCF Margin is 2.47%, which was down 528100.0% from 73.46% recorded in Q2 2025.
  • In the past 5 years, Emergent BioSolutions' FCF Margin registered a high of 85.8% during Q2 2024, and its lowest value of 121.18% during Q1 2023.
  • In the last 5 years, Emergent BioSolutions' FCF Margin had a median value of 13.45% in 2021 and averaged 7.04%.
  • Per our database at Business Quant, Emergent BioSolutions' FCF Margin plummeted by -983800bps in 2023 and then skyrocketed by 1233600bps in 2024.
  • Quarter analysis of 5 years shows Emergent BioSolutions' FCF Margin stood at 38.52% in 2021, then decreased by -27bps to 28.1% in 2022, then crashed by -73bps to 7.48% in 2023, then tumbled by -660bps to 41.91% in 2024, then skyrocketed by 94bps to 2.47% in 2025.
  • Its FCF Margin stands at 2.47% for Q3 2025, versus 73.46% for Q2 2025 and 6.66% for Q1 2025.